HERCULES, Calif. / May 30, 2024 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Anette Engelhardt will join the company as its new Executive Vice President and President of the Clinical Diagnostics Group, effective June 10, 2024.

Ms. Engelhardt joins Bio-Rad from Cepheid, a wholly owned subsidiary of Danaher Corporation and a leading global molecular diagnostics company. While at Cepheid, Ms. Engelhardt was Senior Vice President and General Manager overseeing the emerging growth opportunities business, as well as Senior Vice President of global research and development, strategy, product management and marketing functions supporting the company’s extensive product portfolio.

Prior to Cepheid, Ms. Engelhardt held several senior positions at bioMerieux Inc., a global leader in in vitro diagnostics, including Senior Vice President of the company’s new technologies franchise and microbiology business unit. In these roles, she was responsible for developing and implementing product and market strategies for bioMerieux’s range of microbiology-related reagents, instruments, and services, as well as leveraging and commercializing new technologies. Ms. Engelhardt’s career also includes tenure as CEO of privately held AB BIODISK, where she managed the in vitro diagnostics company’s post-acquisition integration into bioMerieux. She began her career as a process engineer at AB BIODISK and holds a combined Master of Science and Bachelor of Science degree in Chemical Engineering and Polymer Technology from the Royal Institute of Technology in Stockholm, Sweden.

“We are very pleased to welcome Anette Engelhardt as President of our Clinical Diagnostics Group,” stated Andy Last, Bio-Rad’s Executive Vice President and Chief Operating Officer. “Anette brings to Bio-Rad extensive operational experience and a successful track record in developing and commercializing novel diagnostics products across multiple markets. We are confident her expertise will help advance our clinical diagnostics strategy to extend Bio-Rad’s core diagnostics and develop new products and market entries for our clinical business.”

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 8,000 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.

Forward-Looking Statements

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan," "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.